Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seclidemstat Rollover Study
NCT05266196Phase 2Enrolling by invitation
- Sponsor
- Salarius Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Seclidemstat in Ewing sarcoma, myxoid liposarcoma (MLPS), desmoplastic small round cell tumor (DSRCT) and 6 more (2 arms), sponsored by Salarius Pharmaceuticals. Primary endpoint: Length of time receiving study treatment up to 5 years. Started Jan 2022; status: enrolling by invitation.
02
Drugs
Seclidemstat
03
Conditions
Ewing sarcomamyxoid liposarcoma (MLPS)desmoplastic small round cell tumor (DSRCT)extraskeletal myxoid chondrosarcoma (EMC)angiomatoid fibrous histiocytoma (AFH)
Beyond the preview
Go deeper on NCT05266196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266196.